SR146131, a cholecystokinin-A receptor agonist, antagonizes prepulse inhibition deficits produced by dizocilpine and DOI

Psychopharmacology

Volumn 164, Issue 3, 2002, Pages 285-293

  Shilling, P D ^a   Feifel, D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5HT2A receptors; Amphetamine; Antipsychotic drugs; Cholecystokinin; Dopamine; NMDA receptors; Schizophrenia; Serotonin

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; AMPHETAMINE; CHOLECYSTOKININ A RECEPTOR STIMULATING AGENT; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DIZOCILPINE; DOPAMINE RECEPTOR STIMULATING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN 2A AGONIST; SR 146131; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM;

AMPHETAMINE; AMPHETAMINES; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; INDOLES; INHIBITION (PSYCHOLOGY); MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHOLECYSTOKININ; STARTLE REACTION; THIAZOLES;

EID: 0036430098     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1214-z     Document Type: Article

References (61)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999) Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156:1686-1696
2. Bakshi VP, Geyer MA (1997) Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J Pharmacol Exp Ther 283:666-674
3. Bakshi VP, Geyer MA (1998) Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J Neurosci 18:8394-8401
4. Bakshi VP, Swerdlow NR, Geyer MA (1994) Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271:787-794
5. Bakshi VP, Swerdlow NR, Braff DL, Geyer MA (1998) Reversal of isolation rearing-induced deficits in prepulse inhibition by Seroquel and olanzapine. Biol Psychiatry 43:436-445
6. Baptista T (1999) Body weight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psychiatr Scand 100:3-16
7. Bignon E, Alonso R, Arnone M, Boigegrain R, Brodin R, Gueudet C, Heaulme M, Keane P, Landi M, Molimard JC, Olliero D, Poncelet M, Seban E, Simiand J, Soubrie P, Pascal M, Maffrand JP, Le Fur G (1999a) SR146131: A new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization. J Pharmacol Exp Ther 289:752-761
8. Bignon E, Bachy A, Boigegrain R, Brodin R, Cottineau M, Gully D, Herbert JM, Keane P, Labie C, Molimard JC, Olliero D, Oury-Donat F, Petereau C, Prabonnaud V, Rockstroh MP, Schaef-fer P, Servant O, Thurneyssen O, Soubri3 P, Pascal M, Maffrand JP, Le Fur G (1999b) SR146131: A new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies. J Pharmacol Exp Ther 289:742-751
9. Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47:181-188
10. Bunney BS, Chiodo LA, Freeman AS (1985) Further studies on the specificity of proglumide as a selective cholecystokinin antagonist in the central nervous system. Ann NY Acad Sci 448:345-351
11. Chiodo LA, Bunney BS (1983) Proglumide: Selective antagonism of excitatory effects of cholecystokinin in central nervous system. Science 219:1449-1451
12. Chiodo LA, Freeman AS, Bunney BS (1987) Electrophysiological studies on the specificity of the cholecystokinin antagonist proglumide. Brain Res 410:205-211
13. Crawley JN (1991) Cholecystokinin-dopamine interactions. Trends Pharmacol Sci 12:232-236
14. Crawley JN (1992) Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. J Neurosci 12:3380-3391
15. Crawley JN (1994) Cholecystokinin modulates dopamine-mediated behaviors. Differential actions in medial posterior versus anterior nucleus accumbens. Ann NY Acad Sci 713:138-142
16. Crawley JN, Corwin RL (1994) Biological actions of cholecystokinin. Peptides 15:731-755
17. Crawley JN, Hays SF, Paul SM (1981) Vagotomy abolishes the inhibitory effects of cholecystokinin on rat exploratory behaviors. Eur J Pharmacol 73:379
18. Depoortere R, Perrault G, Sanger DJ (1997) Some, but not all, antipsychotic drugs potentiate a low level of prepulse inhibition shown by rats of the Wistar strain. Behav Pharmacol 8: 364-372
19. Dourish CT, Ruckert AC, Tattersall FD, Iversen SD (1989) Evidence that decreased feeding induced by systemic injection of cholecystokinin is mediated by CCK-A receptors. Eur J Pharmacol 173:233-234
20. Feifel D, Reza T, Robeck S (1999a) Antipsychotic potential of CCK-based treatments: An assessment using the prepulse inhibition model of psychosis. Neuropsychopharmacology 20:141-149
21. Feifel D, Reza TL, Wustrow DJ, Davis MD (1999b) Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J Pharmacol Exp Ther 288:710-713
22. Fink H, Rex A, Voits M, Voigt JP (1998) Major biological actions of CCK-a critical evaluation of research findings. Exp Brain Res 123:77-83
23. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology 156:117-154
24. Gibbs J, Young RC, Smith GP (1973) Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 84:488-495
25. Graham WC, Hill DR, Woodruff GN, Sambrook MA, Crossman AR (1991) Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey. Neurosci Lett 131:129-134
26. Hamilton ME, Freeman AS (1995) Effects of administration of cholecystokinin into the VTA on DA overflow in nucleus accumbens and amygdala of freely moving rats. Brain Res 688:134-142
27. Heidbreder C, Gewiss M, De Potter W, De Witte P (1992) Regional amines levels in the rat brain following intra-accumbens cholecystokinin and intraperitoneal amphetamine pre-treatment. Arch Int Physiol Biochim Biophys 100:267-273
28. Hill DR, Shaw TM, Graham W, Woodruff GN (1990) Autoradiographical detection of cholecystokinin-A receptors in primate brain using 125I-Bolton Hunter CCK-8 and 3H-MK-329. J Neurosci 10:1070-1081
29. Johansson C, Jackson DM, Zhang J, Svensson L (1995) Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: Effects of antipsychotics and other agents in rats. Pharmacol Biochem Behav 52:649-654
30. Kadar T, Penke B, Kovacs K, Telegdy G (1985) Inhibition of haloperidol-induced catalepsy by cholecystokinin octapeptides after central administration to rats. Neuropharmacology 24:577-580
31. Kaneyuki T, Morimasa T, Shohmori T (1989) Action of peripherally administered cholecystokinin on monoaminergic and GABAergic neurons in the rat brain. Acta Med Okayama 43:153-159
32. Kapur S, Remington G (2001) Dopamine D (2) receptors and their role in atypical antipsychotic action: Still necessary and may even be sufficient. Biol Psychiatry 50:873-883
33. Kihara T, Ikeda M, Matsubara K, Matsushita A (1993) Differential effects of ceruletide on amphetamine-induced behaviors and regional dopamine release in the rat. Eur J Pharmacol 230:271-277
34. Laterra J, Goldstein GW (2000) Ventricular organization of cerebrospinal fluid: Blood-brain barrier, brain edema, and hydrocephalus. In: Kandel ER, Schwartz JH, Jessell TM (eds) Principles of Neural Science. McGraw-Hill, New York, pp 1288-1301
35. Mansbach RS, Geyer MA (1989) Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2:299-308
36. Mansbach RS, Geyer MA, Braff DL (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology 94:507-514
37. Marshall FH, Barnes S, Hughes J, Woodruff GN, Hunter JC (1991) Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. J Neurochem 56:917-922
38. Mercer LD, Beart PM (1997) Histochemistry in rat brain and spinal cord with an antibody directed at the cholecystokinin A receptor. Neurosci Lett 225:97-100
39. Montgomery SA, Green MC (1988) The use of cholecystokinin in schizophrenia: A review. Psychol Med 18:593-603
40. Noble F, Wank SA, Crawley JN, Bradwejn J, Seroogy KB, Hamon M, Roques BP (1999) International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 51:745-81
41. Paxinos G (1995) The Rat Nervous System, 2nd edn. Academic Press, New York
42. Rex A, Marsden CA, Fink H (1997) Cortical 5-HT-CCK interactions and anxiety-related behaviour of guinea-pigs: A microdialysis study. Neurosci Lett 228:79-82
43. Schaeffer P, Nestor AL, Prabonnaud V, Bachy A, Laplace MC, Keane PE, Bignon E, Herbert JM (2000) Characterisation of the effects of SR146131, a novel non-peptide CCK (1) receptor agonist, on IMR-32 human neuroblastoma cells. Eur J Pharmacol 397:303-310
44. Shilling PD, Feifel D (2002) Decreased haloperidol-induced potentiation of zif268 mRNA expression in the nucleus accumbens shell and the dorsal lateral striatum of rats lacking cholecystokinin-A receptors. Synapse 43:134-138
45. Sipes TA, Geyer MA (1994) Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology 33:441-448
46. Sipes TE, Geyer MA (1997) DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum. Brain Res 761:97-104
47. Skirboll LR, Grace AA, Hommer DW, Rehfeld J, Goldstein M, Hokfelt T, Bunney BS (1981) Peptide-monoamine coexistence: Studies of the actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons. Neuroscience 6:2111-2124
48. Stanton JM (1995) Weight gain associated with neuroleptic medication: A review. Schizophr Bull 21:463-472
49. Swerdlow NR, Geyer MA (1998) Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24:285-301
50. Swerdlow NR, Bakshi V, Waikar M, Taaid N, Geyer MA (1998) Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology 140:75-80
51. Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: Current knowledge and future challenges. Psychopharmacology 156:194-215
52. Talvik-Lotfi M, Nyberg S, Nordstrom AL, Ito H, Halldin C, Brunner F, Farde L (2000) High 5HT2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharmacology 148:400-403
53. Varty GB, Bakshi VP, Geyer MA (1999) M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20:311-321
54. Vasar EE, Otter M, Ryago LK (1985) Intracerebroventricular administration of cholecystokinin inhibits the activity of the dopaminergic and serotoninergic systems of the brain. Neurosci Behav Physiol 15:232-236
55. Vasar E, Harro J, Lang A, Pôld A, Soosaar A (1991) Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse. Psychopharmacology 105:393-399
56. Vickroy TW, Bianchi BR, Kerwin JFJ, Kopecka H, Nadzan AM (1988) Evidence that type A CCK receptors facilitate dopamine efflux in rat brain. Eur J Pharmacol 152:371-372
57. Wetterling T (2001) Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 24:59-73
58. Widerlöv E, Kalivas PW, Lewis MH, Prange AJ Jr, Breese GR (1983) Influence of cholecystokinin on central monoaminergic pathways. Regul Pept 6:99-109
59. Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP (2001) Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 22:2329-2343
60. You ZB, Herrera-Marschitz M, Pettersson E, Nylander I, Goiny M, Shou HZ, Kehr J, Godukhin O, Hökfelt T, Terenius L, Ungerstedt U (1996) Modulation of neurotransmitter release by cholecystokinin in the neostriatum and substantia nigra of the rat: Regional and receptor specificity. Neuroscience 74:793-804
61. You ZB, Godukhin O, Goiny M, Nylander I, Ungerstedt U, Terenius L, Hökfelt T, Herrera-Marschitz M (1997) Cholecystokinin-8S increases dynorphin B, aspartate and glutamate release in the fronto-parietal cortex of the rat via different receptor subtypes. Naunyn-Schmiedeberg's Arch Pharmacol 355:576-581